logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Osteoporosis In Endocrine Disorders

    Medications for Osteoporosis In Endocrine Disorders

    FiltersReset Filters
    3 results

    • alendronate sodium

      (Alendronate Sodium)
      Hikma Pharmaceuticals USA Inc.
      Usage: Alendronate sodium is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. It reduces fracture incidence, though the optimal treatment duration hasn't been established, requiring periodic re-evaluation of the need for continued therapy.

    • risedronate sodium

      (risedronate sodium)
      Sun Pharmaceutical Industries, Inc.
      Usage: Risedronate sodium is indicated for the treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease of bone. It reduces vertebral and nonvertebral osteoporosis-related fractures and helps increase bone mass in men. Regular re-evaluation of therapy is recommended.

    • risedronate sodium

      (Risedronate Sodium)
      Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd
      Usage: Risedronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, preventing osteoporosis induced by glucocorticoids, and treating Paget's disease. Regular assessment for continued therapy is necessary due to undetermined optimal duration of use.